In this episode of the China biopharma English-language podcast, Xu Hu talks about China’s drug regulator finalizing trial data protection measures for drugs registered in the country, and some of the impacts these may have on future licensing deals involving the China market and company strategies in managing product lifecycle and market access in China.

Here are links to the stories this episode is based on:

Impact Of China’s New Data Protection On Deals, Corporate Strategies;

China Finalizes Data Protection Periods;

China Plans Clinical Data Protection By Product Category For First Time